Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study.
|Title||Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study.|
|Publication Type||Journal Article|
|Year of Publication||2016|
|Authors||Ganz PA, Petersen L, Bower JE, Crespi CM|
|Journal||J Clin Oncol|
|Date Published||2016 Mar 10|
|Keywords||Antineoplastic Agents, Hormonal, Aromatase Inhibitors, Breast Neoplasms, Cohort Studies, Female, Humans, Middle Aged, Mind-Body Relations, Metaphysical, Psychophysiology, Quality of Life, Self Report, Tamoxifen|
PURPOSE: To examine patterns of health and symptoms associated with the initiation of adjuvant endocrine therapy (ET) for primary breast cancer treatment.
PATIENTS AND METHODS: The mind-body study (MBS) observational cohort participants provided self-reported data on physical and mental health, ET-related symptoms, as well as depression, fatigue, and sleep obtained at enrollment (after primary treatment, prior to initiation of ET) and 6 and 12 months later. Longitudinal trajectories of outcome variables among three patient groups (no ET, aromatase inhibitor [AI], or tamoxifen) were compared by using linear mixed models.
RESULTS: Two-thirds of the 186 women initiated ET, which was evenly split between AI and tamoxifen, and no significant differences were observed in self-reported measures among the groups at baseline or in covariate-adjusted analyses. Physical health scores were below normative levels initially and improved over time, but the AI group had a significantly lower score at 12 months (P = .05); mental health scores were within the normal range, were similar in each group, and did not change over time. The no-ET group showed either stable or declining symptom severity, whereas the ET groups often showed increased severity over time, and the AI group reported more severe musculoskeletal (P = .02), hot flash (P = .02), and cognitive problems (P = .006) at one or both of the follow-up time points compared with the no-ET group. The tamoxifen group had higher levels of hot flashes (P = .002), cognitive problems (P = .016), and bladder problems (P = .02) than the no-ET group.
CONCLUSION: Attention should be given to the increased symptom burden associated with ET, and better efforts should be made to address patient-reported outcomes.
|Alternate Journal||J. Clin. Oncol.|
|PubMed Central ID||PMC4872009|
|Grant List||P30 CA16042 / CA / NCI NIH HHS / United States |
R01 CA 109650 / CA / NCI NIH HHS / United States